Ocugen, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ocugen, Inc. is a clinical-stage biotechnology firm dedicated to advancing novel gene and cell therapies, alongside vaccines, to address a range of significant health challenges. The company's innovative pipeline emphasizes its modifier gene therapy platform, which employs a gene-agnostic strategy designed to potentially treat numerous retinal diseases with a single therapeutic agent. Leading their ocular initiatives, OCU400 is currently undergoing Phase 3 clinical trials for inherited retinal dystrophies like Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA), with plans for Biologics License Application (BLA) and Marketing Authorization Application (MAA) submissions anticipated by mid-2026. Another key program, OCU410ST, a modifier gene therapy for Stargardt disease, recently commenced its Phase 2/3 pivotal confirmatory trial, targeting a BLA filing in 2027. Additionally, OCU410, aimed at geographic atrophy secondary to dry age-related macular degeneration (dAMD), completed Phase 2 dosing and is slated for Phase 3 in 2026. Beyond gene therapies, Ocugen is progressing OCU200, a recombinant fusion protein, now in Phase 1 for conditions such as diabetic macular edema (DME), diabetic retinopathy, and wet AMD. The company is also involved in vaccine development, including an inhaled COVID-19 vaccine (OCU500) within a NIAID-funded trial, and has a cell therapy, NeoCart, in Phase 3 for knee cartilage repair. Ocugen engages in strategic alliances to propel its development and commercialization efforts. It maintains a collaboration with CanSino Biologics Inc. for the co-development and manufacturing of its gene therapy candidates, which includes commercialization rights in Greater China. The company also recently entered a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400, providing upfront and milestone payments, as well as royalties. Furthermore, Ocugen continues its partnership with Bharat Biotech for the commercialization of COVAXIN in the United States. The company is headquartered in Malvern, Pennsylvania.
Ocugen to Participate in Upcoming July Industry Conferences
Ocugen to Participate in Upcoming July Industry Conferences
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028
Ocugen to Participate in Upcoming June Investor and Industry Conferences
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
Ocugen (OCGN) Upgraded to Buy: Here's Why
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
Ocugen Provides Business Update with First Quarter 2026 Financial Results
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
Ocugen to Present at April 2026 Investor and Industry Conferences
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy